Synergy between Human Peptide LL-37 and Polymyxin B against Planktonic and Biofilm Cells of and .

The rise in antimicrobial resistant bacteria is limiting the number of effective treatments for bacterial infections. and are two of the pathogens with the highest prevalence of resistance, and with the greatest need for new antimicrobial agents. Combinations of antimicrobial peptides (AMPs) and antibiotics that display synergistic effects have been shown to be an effective strategy in the development of novel therapeutic agents.

The Potential of Human Peptide LL-37 as an Antimicrobial and Anti-Biofilm Agent.

The rise in antimicrobial resistant bacteria threatens the current methods utilized to treat bacterial infections. The development of novel therapeutic agents is crucial in avoiding a post-antibiotic era and the associated deaths from antibiotic resistant pathogens. The human antimicrobial peptide LL-37 has been considered as a potential alternative to conventional antibiotics as it displays broad spectrum antibacterial and anti-biofilm activities as well as immunomodulatory functions.